Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06534450 · ClinicalTrials.gov registry record · Phase 3
The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics
A Phase 3 study of Aging, sponsored by Dobri Kiprov.
- Active
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06534450: Active Phase 3 study of Aging, sponsored by Dobri Kiprov.
NCT06534450 is a Phase 3 study of Aging that is active but no longer recruiting, run by Dobri Kiprov. The registered enrollment target is 40 participants, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06534450, a Phase 3 study of Aging, is active but no longer recruiting, sponsored by Dobri Kiprov.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assure the safety of long term therapeutic plasma exchange (TPE) with and without Intravenous Immunoglobulin (IVIG) and its effects on biomarkers and epigenetic biologic clocks in forty individuals. The main question is to assure the safety from long term TPE using changes in clinical and laboratory outcomes and also evaluating changes on additional blood biomarkers and epigenetic clocks during and after TPE treatment. Researchers will compare the TPE treatment group to the Sham treatment group to identify changes due to TPE. Participants will receive six TPE or Sham treatments over one of two treatment schedules and may receive IVIG with treatment.
Conditions Studied
Interventions
- DEVICE Sham
- DRUG IVIG
- DEVICE Therapeutic Plasma Exchange
Study Locations (1)
California
- Global Apheresis - Mill Valley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-09-12 |
| Est. Completion | 2025-08 |
| Phase | Phase 3 |
What the registry record for NCT06534450 still lists
NCT06534450 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 2,195-participant average among 262 other Aging trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Aging appearing as the primary indexed condition, and to 3 interventions - of which Sham is the first listed.
NCT06534450 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06534450 about?
NCT06534450 is a clinical study titled "The Effects Of Therapeutic Plasma Exchange (TPE) On Age Related Biomarkers And Epigenetics". The goal of this clinical trial is to assure the safety of long term therapeutic plasma exchange (TPE) with and without Intravenous Immunoglobulin (IVIG) and its effects on biomarkers and epigenetic biologic clocks in forty individuals. The main question is to assure the safety from long term TPE us...
What is the current status of trial NCT06534450?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2022-09-12. Estimated completion is 2025-08.
What conditions does trial NCT06534450 study?
This clinical trial studies the following conditions: Aging.
What interventions are being tested in trial NCT06534450?
The interventions under investigation include: Sham (DEVICE), IVIG (DRUG), Therapeutic Plasma Exchange (DEVICE).
Who is sponsoring clinical trial NCT06534450?
This trial is sponsored by Dobri Kiprov, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06534450 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aging
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06534450's enrollment target sits among peer trials
40 173rd of 262 higher than 84 of 262 other Aging trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aging trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
SMART Exercise for PAD
RECRUITING · Phase 3
-
ACHIEVE Brain Health Follow-Up Study
ACTIVE NOT RECRUITING · Phase 3
-
Combination Gerotherapeutic Interventions for Healthspan Improvement
ACTIVE NOT RECRUITING · Phase 3
-
SeniorWISE: Improving Everyday Memory in At-Risk Elderly
COMPLETED · Phase 3
-
Exercise, Executive Processes and the Aging Brain
COMPLETED · Phase 3
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI